<DOC>
	<DOCNO>NCT00002454</DOCNO>
	<brief_summary>RATIONALE : Vaccines make papilloma virus cell may make body build immune response kill papilloma cell . PURPOSE : Phase II trial study effectiveness papilloma virus vaccine treat young patient recurrent papilloma larynx .</brief_summary>
	<brief_title>Papilloma Virus Vaccine Therapy Treating Young Patients With Recurrent Papilloma Larynx</brief_title>
	<detailed_description>OBJECTIVES : I . Determine immune response patient juvenile papilloma larynx treat autogenous vaccine derive patient 's tumor . OUTLINE : Patients receive autogenous papilloma vaccine intradermally subcutaneously weekly 20 week . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis severe recurrent juvenile papilloma larynx require surgery least 4 time per year Condition must exist 1 year PATIENT CHARACTERISTICS : Age : 1 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>lung papilloma</keyword>
</DOC>